The company ditches lorigerlimab in prostate cancer.
ApexOnco Front Page
Recent articles
But the Day One deal is still 29% below where the shares stood at the start of this year.
Summit and Nuvalent have scored prized plenary spots.
Inclacumab fails, and osivelotor is on hold.
Shortly after ponsegromab, visugromab is to start phase 2/3.
J&J, Astra, Pfizer and others move yet more ADCs into human studies.
Meanwhile, ASK Pharm challenges Hutchmed in cMet.
Progress with three bispecific molecules is rewarded with a $120m equity raise.
